Gyre Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Gyre Therapeutics, Inc. filed its Q1 2024 10-Q, detailing financial status and significant agreements.</b>

AI Summary

GYRE THERAPEUTICS, INC. (GYRE) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Gyre Therapeutics, Inc. (GYRE) filed a 10-Q report for the period ending March 31, 2024. The company was formerly known as Catalyst Biosciences, Inc. and Targacept Inc. Key agreements mentioned include the GC Biopharma Corp Asset Purchase Agreement and Contingent Value Rights Agreement. Significant customers include Shanghai Pharmaceuticals Holding Company Limited, Sinopharm Group Company Limited, and China Resources Pharmaceutical Group Limited. The filing references subsequent events in April and May 2024, including the Jiangsu Wangao Agreement.

Why It Matters

For investors and stakeholders tracking GYRE THERAPEUTICS, INC., this filing contains several important signals. The filing provides a snapshot of Gyre Therapeutics' financial health and operational activities for the first quarter of 2024, including details on assets, liabilities, and equity. Information on customer concentration risk and related party transactions offers insight into the company's business relationships and potential dependencies.

Risk Assessment

Risk Level: medium — GYRE THERAPEUTICS, INC. shows moderate risk based on this filing. The company's financial performance and future prospects are subject to risks associated with product development, regulatory approvals, and market competition, as indicated by the various agreements and customer relationships detailed in the filing.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-Q to assess Gyre Therapeutics' current financial position and future growth potential.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed period of report)
• 2024-05-13 — Filing Date (Filed as of date)
• 2023-01-01 — Q1 2023 Start Date (Reporting period for Q1 2023)
• 2023-03-31 — Q1 2023 End Date (Reporting period for Q1 2023)
• 2024-01-01 — Q1 2024 Start Date (Reporting period for Q1 2024)
• 2024-03-31 — Q1 2024 End Date (Reporting period for Q1 2024)

Key Players & Entities

• GYRE THERAPEUTICS, INC. (company) — Filer name
• GYRE (company) — Ticker symbol
• CATALYST BIOSCIENCES, INC. (company) — Former company name
• TARGACEPT INC (company) — Former company name
• GCBiophrarma Corp Asset Purchase Agreement (company) — Agreement mentioned
• Shanghai Pharmaceuticals Holding Company Limited (company) — Customer mentioned
• Sinopharm Group Company Limited (company) — Customer mentioned
• China Resources Pharmaceutical Group Limited (company) — Customer mentioned

FAQ

Risk Factors

• Product Concentration Risk [medium — market]: The company faces risk due to concentration of its revenue from a single product.
• Customer Concentration Risk [medium — market]: A significant portion of the company's revenue is derived from a small number of customers.

Key Dates

• 2024-03-31: Quarterly Report End Date — Covers financial and operational data for Q1 2024.
• 2024-05-13: Filing Date — Date the 10-Q was officially submitted to the SEC.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share GYRE The Nasdaq Capital M

Filing Documents

• gyre-20240331.htm (10-Q) — 1956KB
• gyre-ex31_1.htm (EX-31.1) — 16KB
• gyre-ex31_2.htm (EX-31.2) — 16KB
• gyre-ex32_1.htm (EX-32.1) — 12KB
• gyre-ex32_2.htm (EX-32.2) — 12KB
• 0000950170-24-058642.txt (&nbsp;) — 9724KB
• gyre-20240331.xsd (EX-101.SCH) — 1448KB
• gyre-20240331_htm.xml (XML) — 1860KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 2 Item 1.

Financial Statements

Financial Statements: 2 Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 2 Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Convertible Preferred Stock and Equity for the three months ended March 31, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited) 6 Notes to the Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 34

OTHER INFORMATION

PART II. OTHER INFORMATION 35 Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36 Exhibit Index 36

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FIN ANCIAL STATEMENTS

ITEM 1. FIN ANCIAL STATEMENTS Gyre Therapeutics, Inc. Condensed Consolidat ed Balance Sheets (In thousands, except share and per share amounts) March 31, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 29,785 $ 33,509 Short-term bank deposits 7,567 — Accounts and note receivables, net 15,458 15,552 Other receivables from GNI 1,287 1,287 Inventories, net 4,939 4,281 Prepaid assets 1,790 1,547 Other current assets 1,897 1,045 Total current assets 62,723 57,221 Property and equipment, net 23,564 23,288 Long-term receivable from GCBP 4,780 4,722 Intangible assets, net 196 205 Right-of-use assets 359 489 Land use rights, net 1,480 1,493 Deferred tax assets 5,000 4,695 Long-term certificates of deposit 23,106 23,431 Other assets, noncurrent 802 995 Total assets $ 122,010 $ 116,539 Liabilities, convertible preferred stock, and equity Current liabilities: Accounts payable $ 330 $ 355 Deferred revenue 35 39 Due to related parties 1,362 1,369 CVR excess closing cash payable 422 1,085 Accrued expenses and other current liabilities 10,767 11,935 Income tax payable 6,470 5,054 Operating lease liabilities, current 100 210 Total current liabilities 19,486 20,047 Operating lease liabilities, noncurrent 175 199 Deferred government grants 203 213 CVR derivative liability, noncurrent 4,780 4,722 Warrant liability, noncurrent 8,547 12,835 Other noncurrent liabilities 48 49 Total liabilities 33,239 38,065 Commitments and Contingencies (Note 12) Convertible Preferred Stock, $ 0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively — 64,525 Stockholders' equity: Common stock, $ 0.001 par value, 400,000,000 shares authorized; 85,4

View Full Filing

View this 10-Q filing on SEC EDGAR